QQ客服 官方微博 反馈留言

	PHARMACOKINETICS (PK) OF CRIZOTINIB (PF-02341066), A DUAL ALK/C-MET INHIBITOR, FOLLOWING ADMINISTRATION OF MULTIPLE ORAL DOSES TO PATIENTS WITH ADVANCED ALK-POSITIVE NSCLC IN CHINA
	Tan, Weiwei; O'Gorman, Melissa; Lanzalone, S.; Wilner, Keith; Boyd, Jason; Liu, Xiaoquing; Wu, Yi-long; Qin, Shukui; Han, Baohui; Shi, Yuankai
	2012
卷号	7期号:11页码:S491-S491
关键词	crizotinib pharmacokinetics ALK NSCLC
ISSN号	1556-0864
URL标识	查看原文
收录类别	SCIE
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/6722509
专题	中国医学科学院 北京协和医学院
推荐引用方式 GB/T 7714	Tan, Weiwei,O'Gorman, Melissa,Lanzalone, S.,et al. PHARMACOKINETICS (PK) OF CRIZOTINIB (PF-02341066), A DUAL ALK/C-MET INHIBITOR, FOLLOWING ADMINISTRATION OF MULTIPLE ORAL DOSES TO PATIENTS WITH ADVANCED ALK-POSITIVE NSCLC IN CHINA[J],2012,7(11):S491-S491.
APA	Tan, Weiwei.,O'Gorman, Melissa.,Lanzalone, S..,Wilner, Keith.,Boyd, Jason.,...&Shi, Yuankai.(2012).PHARMACOKINETICS (PK) OF CRIZOTINIB (PF-02341066), A DUAL ALK/C-MET INHIBITOR, FOLLOWING ADMINISTRATION OF MULTIPLE ORAL DOSES TO PATIENTS WITH ADVANCED ALK-POSITIVE NSCLC IN CHINA.,7(11),S491-S491.
MLA	Tan, Weiwei,et al."PHARMACOKINETICS (PK) OF CRIZOTINIB (PF-02341066), A DUAL ALK/C-MET INHIBITOR, FOLLOWING ADMINISTRATION OF MULTIPLE ORAL DOSES TO PATIENTS WITH ADVANCED ALK-POSITIVE NSCLC IN CHINA".7.11(2012):S491-S491.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。